IDH1 Gene Mutation clinical trials at UCSF

2 in progress, 1 open to eligible people

IDH1 gene mutation is a genetic alteration that can lead to cancer. UCSF is testing a new treatment using BGB-290 and temozolomide for brain tumors. These trials are examining the side effects and the most effective dose to use in treating these tumors.

Showing trials for

  • BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas

    open to eligible people ages 13-25

    This phase I trial studies the side effects and best dose of BGB-290 and temozolomide in treating adolescents and young adults with IDH1/2-mutant grade I-IV glioma that is newly diagnosed or has come back. BGB-290 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving BGB-290 and temozolomide may work better in treating adolescents and young adults with IDH1/2-mutant grade I-IV glioma.

    San Francisco, California and other locations

  • Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)

    Sorry, in progress, not accepting new patients

    This phase II Pediatric MATCH trial studies how well ivosidenib works in treating patients with solid tumors that have spread to other places in the body (advanced), lymphoma, or histiocytic disorders that have IDH1 genetic alterations (mutations). Ivosidenib may block the growth of cancer cells that have specific genetic changes in an important signaling pathway called the IDH pathway.

    Oakland, California and other locations

Our lead scientists for IDH1 Gene Mutation research studies include .

Last updated: